Sam Brusco, Associate Editor02.24.21
TransEnterix has changed its corporate name to Asensus Surgical, reflecting the firm's vision to shape surgery’s future by integrating computer vision and machine learning with surgical robotics. The company's stock will begin trading under the new ticker symbol, NYSE American: ASXC, and name, Asensus Surgical Inc., at trading’s open on March 5.
Asensus’ Senhance Surgical System is a first-of-its-kind digital laparoscopic platform that leverages augmented intelligence to boost performance and patient outcomes via machine learning. Senhance provides surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization. According to Asensus, it’s the first platform to offer 3 mm instruments. Senhance is currently being used by over 100 active surgeons across three continents, with over 4,000 procedures performed across a wide variety of surgical specialties.
“As we work to create the future of surgery we need to enable surgeons to take the best surgical practices and techniques from everywhere and enable them to be leveraged anywhere; this is what digital technology has enabled us to do,” Asensus president and CEO Anthony told the press. “As the company evolves from a robotics company to a digital surgery company, the rebrand better reflects our vision and we know that Asensus has the technology, the team, and the opportunity to create a new paradigm in best surgical practices and techniques we call performance-guided surgery.”
Here’s the company’s thought process behind the new name. Sensus is Latin for “cognition,” making the connection between surgeons’ knowledge and the augmented intelligence technology to perceive and develop future innovations. “A” in front of “sensus” lends itself to the idea of augmented intelligence and being at the forefront of innovation. Asensus also speaks to “ascending” and “elevating,” aligning with the firm’s mission to elevate robotic surgery by driving predictable outcomes, optimizing resources and costs, and working with hospital systems seeking to employ innovative healthcare strategies.
Asensus’ Senhance Surgical System is a first-of-its-kind digital laparoscopic platform that leverages augmented intelligence to boost performance and patient outcomes via machine learning. Senhance provides surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization. According to Asensus, it’s the first platform to offer 3 mm instruments. Senhance is currently being used by over 100 active surgeons across three continents, with over 4,000 procedures performed across a wide variety of surgical specialties.
“As we work to create the future of surgery we need to enable surgeons to take the best surgical practices and techniques from everywhere and enable them to be leveraged anywhere; this is what digital technology has enabled us to do,” Asensus president and CEO Anthony told the press. “As the company evolves from a robotics company to a digital surgery company, the rebrand better reflects our vision and we know that Asensus has the technology, the team, and the opportunity to create a new paradigm in best surgical practices and techniques we call performance-guided surgery.”
Here’s the company’s thought process behind the new name. Sensus is Latin for “cognition,” making the connection between surgeons’ knowledge and the augmented intelligence technology to perceive and develop future innovations. “A” in front of “sensus” lends itself to the idea of augmented intelligence and being at the forefront of innovation. Asensus also speaks to “ascending” and “elevating,” aligning with the firm’s mission to elevate robotic surgery by driving predictable outcomes, optimizing resources and costs, and working with hospital systems seeking to employ innovative healthcare strategies.
